Warsaw-based Britenet Med has been awarded a €1 million grant from the European Institute of Innovation and Know-how (EIT) Well being to advance MoodMon, an AI-driven instrument designed to enhance the administration and therapy of continual affective issues.
The funding was a part of EIT Well being’s notable Flagship Name, which helps groundbreaking healthcare improvements throughout Europe.
“Our mission with MoodMon is to rework the administration of continual affective issues,” mentioned Małgorzata Sochacka, MoodMon originator and Product Supervisor at Britenet Med. “By providing a first-in-class answer that leverages goal knowledge for psychological well being monitoring, we goal to boost affected person outcomes, cut back healthcare prices, and allow professionals to allocate their time extra successfully. The funding and collaboration alternatives supplied by the EIT Well being Flagship Name devoted to the digital transformation of healthcare are essential steps in bringing MoodMon to extra sufferers and healthcare suppliers throughout Europe. However we don’t cease right here . We’re happy to deepen our collaboration by becoming a member of EIT Well being as a associate. We’re assured that it will allow us to attach with further distinctive companions throughout Europe, fostering the trade of data and experience to boost the therapy of psychological sickness on a worldwide scale.”
Based in 2006, Britenet is a Polish IT firm specialising in consulting and outsourcing providers, in relation to this they’ve developed the AI-based system MoodMon to assist remedy for affective issues.
MoodMon affords an revolutionary method to monitoring situations like melancholy and bipolar dysfunction, which influence an estimated 280 million folks worldwide. Conventional monitoring strategies depend on self-observation and subjective reporting, which frequently fall quick in figuring out delicate adjustments in psychological states.
MoodMon leverages AI to analyse behavioural knowledge collected through cellular units and wearables, enabling real-time detection of temper adjustments. Its alert system notifies sufferers, psychiatrists, and caregivers promptly, enhancing therapy outcomes.
Scientific trials have demonstrated MoodMon’s accuracy, with a sensitivity charge of 89.5% and specificity of 98.83%.
The mission is backed by a consortium of establishments throughout Europe, together with Spain’s Fundació de Recerca Clínic Barcelona, Sweden’s Karolinska Institute, and Poland’s Medigent Basis.
The consortium has been established to acquire CE certification, conducting additional scientific trials, and exploring the financial advantages MoodMon affords to healthcare techniques. The event workforce additionally goals to create regulatory frameworks that enable AI-driven units like MoodMon to be up to date with out present process full recertification processes.
EIT Well being’s Flagship Name, designed to deal with Europe’s most urgent healthcare challenges, highlights the significance of collaborative innovation.
“Our Flagship Calls are about catalysing collaborations that may make an actual distinction in European healthcare,” mentioned Joanna Broy, EIT Well being InnoStars Lead for Poland. “MoodMon is a main instance of what could be achieved when revolutionary corporations like Britenet Med come along with main establishments to deal with main well being challenges. This mission showcases the facility of cross-border partnerships in creating options that aren’t solely revolutionary but in addition scalable and impactful. We’re excited to see how MoodMon will enhance the lives of sufferers with affective issues.”
Along with bettering affected person care, MoodMon might considerably cut back healthcare prices. The annual direct price of the melancholy therapy ranges from €3k to €5k per affected person and the common direct price of Bipolar Dysfunction therapy quantities to almost €7k per yr per affected person.
MoodMon’s method might alleviate these monetary pressures by enabling early intervention and higher illness administration.
This funding additionally marks Britenet Med’s deeper integration into EIT Well being’s community, positioning the corporate to collaborate with extra European companions. As EIT Well being has supported over 2,500 startups and introduced 113 healthcare options to market, its position in advancing MoodMon is one other step towards revolutionary options for managing psychological well being.
